Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Cytoreductive surgery with intraperitoneal chemotherapy is one of the most important treatments for patients with colorectal cancer and peritoneal metastasis. For the best survival rates, complete removal of all metastatic lesions is the most important part of treatment, and various surgical procedures are required for the complete cytoreduction. Therefore, the postoperative morbidity rates are higher than those of localized colon cancer surgeries and patients can experience a prolonged recovery period and deterioration of physical activities over a long period. The aim of this study is to investigate the change of quality of life after cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer.

Official Title
-----------------
Recovery of Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Cancer and Pseudomyxoma Peritonei

Conditions
-----------------
Colorectal Cancer Metastatic

Intervention / Treatment
-----------------
* Procedure: Cytoreductive surgery and intraperitoneal chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colorectal cancer peritoneal metastasis Pseudomyxoma peritonei ECOG (Eastern Cooperative Oncology Group) performance status 0-3 Normal bone marrow, kidney, and liver function Patient must sign and date the informed consent Exclusion Criteria: Palliative surgery Palliative intraperitoneal chemotherapy Psychotic disorder Drug abuser

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brief pain inventory (BPI) | Pain recovery after cytoreductive surgery and intraperitoneal chemotherapy | Changes from baseline pain scores at postoperative 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| European Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ)-C30 | Qualify of life questionnaire for cancer patients | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months | 
| EORTC QLQ for colorectal cancer | Quality of life questionnaire for patients with colorectal cancer | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months | 
| Short-form(SF)-36 | Global measure of health-related quality of life | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months | 
| Postoperative morbidity | Incidence and degree of surgical and medical complications after surgery | 90 days after surgery | 
| Postoperative mortality | Incidence of postoperative mortality | 90 days after surgery | 
| Postoperative recovery | Duration of hospital stay after surgery | 150 days after surgery | 
| Brief pain inventory (BPI) | Pain recovery after cytoreductive surgery and intraperitoneal chemotherapy | preoperative, postoperative 3 months, postoperative 6 months, postoperative 24 months |